Response to the Paper by nlR et al. Entitled ‘The Effect of Metformin on Cardiac Fibrosis via Differentiation of Cardiac Fibroblasts'

Molecular and cellular mechanisms underlying the failure of mitochondrial metabolism drugs in cancer clinical trials

“…For instance, a recent stage II clinical trial in ovarian cancer demonstrated better-than-expected overall survival in the metformin-treated group, while a phase III randomized trial that included over 3,600 patients with breast cancer failed to show an improvement in disease-free survival with the addition of metformin to standard-of-care treatment (4). Similarly, metformin failed to show any benefit in phase II randomized trials in NSCLC when combined with chemoradiotherapy (17,18). Although various other studies have shown promising results, the clinical benefit of metformin remains unclear (16).…”